Lisata Therapeutics Collaborates with Alamar Biosciences on Neurodegenerative Disease Research Initiatives
- Alamar Biosciences collaborates with DZNE to enhance neurodegenerative disease research using advanced multiplex panels.
- The CNS Disease Panel 120 measures brain proteins, improving early detection and risk assessment for Alzheimer's disease.
- Alamar's Inflammation Panel 250 profiles immune proteins, aiding in the identification of early biomarkers for neurodegenerative conditions.
Alamar Biosciences Partners with DZNE to Advance Neurodegenerative Disease Research
Alamar Biosciences has entered a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE) to utilize its NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 in the expansive Rhineland Study. This initiative is set to analyze 23,000 plasma samples, aiming to enhance biomarker discovery and deepen the understanding of healthy aging and the onset of neurodegenerative diseases. The Rhineland Study is a significant longitudinal project that investigates the factors contributing to healthy aging and the development of neurodegenerative conditions, providing a crucial platform for scientific inquiry.
Professor Monique Breteler, Director of Population Health Sciences at DZNE, highlights that the integration of Alamar’s advanced multiplex panels will significantly enhance the researchers' ability to decode the molecular signatures associated with brain aging. The CNS Disease Panel 120 is particularly noteworthy for its capacity to measure numerous brain-related proteins from minimal blood volumes, achieving high sensitivity and specificity. A standout feature of this panel is its ability to differentiate between brain-derived phosphorylated tau and total phosphorylated tau in plasma. This capability represents a significant advancement in early detection and risk assessment for conditions such as Alzheimer’s disease, potentially leading to improved patient outcomes through timely interventions.
In addition to the CNS Disease Panel, the Inflammation Panel 250 offers a comprehensive profiling of immune-related proteins associated with aging and neuroinflammation, both critical factors in neurodegenerative diseases. The proteomic data generated from these panels will be integrated with the study's extensive clinical, demographic, and imaging datasets, facilitating the tracking of protein changes over time and aiding in the identification of early biomarkers for neurodegenerative conditions. This collaboration is expected to yield valuable insights into the molecular underpinnings of aging and dementia, ultimately contributing to the development of enhanced early detection and intervention strategies.
In another notable development within the biotechnology sector, Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology from the Canadian Intellectual Property Office. This patent strengthens Anixa's intellectual property portfolio, crucial for addressing the pressing public health need for breast cancer prevention. Meanwhile, Shenzhen Chipscreen Biosciences' subsidiary has obtained FDA approval for its novel drug aimed at treating advanced solid tumors, marking a significant milestone in developing brain-penetrant anti-cancer therapies. These advancements illustrate the dynamic landscape of research and development in the biotechnology industry, with companies like Alamar leading the way in neurodegenerative disease studies.
